

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubarb IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420

Status	RECRUITING
Phase	Phase 2
Sponsor	argenx
Enrollment	70 participants

Key Eligibility Criteria

Inclusion (3)

- Is seropositive for anti-acetylcholine receptor antibodies (AChR-Ab)
- Has confirmed diagnosis of gMG and is Myasthenia Gravis Foundation of America (MGFA) Class II, III, IVa, or IVb
- Has documented immunization against encapsulated bacterial pathogens (Neisseria meningitidis and Streptococcus pneumoniae) within 5 years of ISA screening or is willing to receive immunization at least 14 days before the first study drug administration

Exclusion (4)

- Clinical diagnosis of systemic lupus erythematosus (SLE)
- Any known complement deficiency
- Current administration of a complement inhibitor or received zilucoplan or eculizumab <2 months or ravulizumab <6 months before the first study drug administration
- Patients proven to be refractory to efgartigimod (ie, not achieving a clinically meaningful improvement in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score defined as an improvement of e2 points)

Locations (5 total)

Profound Research LLC - Carlsbad, Carlsbad, California, United States
Visionary Investigators Network, Miami, Florida, United States
Dent Neurologic Institute - Amherst, Amherst, New York, United States
... and 2 more locations